Targeted Market DxNow operates in medical equipment manufacturing with a focus on assisted reproductive technology (ART) and fertility clinics. This presents a sales opportunity to partner with IVF centers, OB/GYN practices, and embryology labs that could adopt ZyMōt sperm separation devices and related consumables.

Strategic Proximity Headquartered near Washington, DC with proximity to USFDA, USPTO, NIH, CMS, and other agencies. Leverage this location to position DxNow as a compliant, regulation-savvy supplier for clinical labs and tender opportunities within government and regulatory ecosystems.

Licensing Advantage DxNow relies on exclusively licensed technologies from BAMM Labs at Harvard/Stanford. Use this as a credibility driver to engage high-end research centers and university-affiliated clinics seeking validated, cutting-edge bio-imaging and microfluidic capabilities.

Growth Signals Recent product launches and reseller partnerships (ZyMōt Starter Pack, exclusive IVF Store distribution) indicate a go-to-market strategy that favors distributor networks and accelerates market penetration in the US fertility sector—a cue to explore additional regional distributors and clinical channel partners.

Financial Footing Small-scale revenue and modest funding suggest early-stage growth. Approach opportunities with value-focused propositions, such as clinical efficiency gains, cost-per-test reductions, and scalable consumables to convert clinics and specialty labs into repeat purchasers.